Quick Answer
iSpecimen Inc. reported Operating Income Loss of -$12.73 million for the year ending 2024.
- iSpecimen Inc. showed a decrease of -14.0% in Operating Income Loss from 2023 to 2024.
- This data is from iSpecimen Inc.'s annual report (Form 10-K), filed with the SEC on April 14, 2025.
- XBRL data for this metric is available from 2020 to 2024 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: -$305.0 thousand | Q3 2020: -$723.1 thousand | Q1 2021: -$942.6 thousand | Q2 2021: -$1.53 million | Q3 2021: -$1.46 million | Q1 2022: -$2.36 million | Q2 2022: -$2.59 million | Q3 2022: -$3.10 million | Q1 2023: -$2.54 million | Q2 2023: -$3.56 million | Q3 2023: -$2.19 million | Q1 2024: -$3.00 million | Q2 2024: -$2.18 million | Q3 2024: -$1.71 million | Q1 2025: -$1.64 million | Q2 2025: -$1.82 million | Q3 2025: -$2.83 million.
- Over the full 5 years of available data (2020 to 2024), iSpecimen Inc.'s Operating Income Loss has declined by 428.9%.
- Historical annual values: Fiscal year 2024: -$12.73 million | Fiscal year 2023: -$11.17 million | Fiscal year 2022: -$10.19 million | Fiscal year 2021: -$5.93 million | Fiscal year 2020: -$2.41 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: